Inhibikase Therapeutics, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Net Loss Per Share

Net Loss Per Share

9 Months Ended

Sep. 30, 2026

12. Net Loss Per Share

Basic net loss per share is calculated by dividing net loss attributable to common shareholders by the weighted-average number of shares outstanding during the period which includes 60,568,910 of Pre-Funded Warrants and shares held in abeyance from date of issuance.

The following potentially dilutive shares of common stock have not been included in the computation of diluted net income (loss) per share for the three and nine months ended September 30, 2026 and 2025, as the result would be anti-dilutive:


	Three Months Ended September 30,				Nine months ended September 30,
	2026		2025		2026		2025
Options to purchase shares of stock		51,238,360		37,853,738		51,238,360		37,853,738
Warrants to purchase shares of stock		118,651,067		119,591,301		118,651,067		119,591,301
Contingently issuable shares (see Note 9):
Restricted common stock		—		1,660,222		—		1,660,222
Contingent consideration		—		2,489,030		—		2,489,030
Total		169,889,427		161,594,291		169,889,427		161,594,291